Skip to Content


New Drug Shows Great Promise for ALL

Conquest - Fall 2011

High Response Rates, Manageable Side Effects

A drug combining an antibody packaged with a potent chemotherapy agent has shown one of the highest response rates ever for the treatment of acute lymphoblastic leukemia (ALL), a cancer of the white blood cells.

Elias Jabbour, M.D.

The drug targets CD22, a protein found on the surface of more than 90% of ALL cases, and is the first of its kind for ALL treatment.

In the Phase II study, the drug saw response rates of more than 50%, particularly significant as patients enrolled in the trial had recurrent or resistant disease.

“The drug is safe,” says Elias Jabbour, M.D., assistant professor in MD Anderson’s Department of Leukemia and a co-investigator on the trial. “Almost all side effects were low grade and manageable. Drug-induced fever was the most common.”

Reported in June 2011 at the 47th Annual Meeting of the American Society of Clinical Oncology.

Care to Comment?

Email the editor to comment on a story or offer suggestions on topics you'd like to see covered in future issues of Conquest and Annual Report.

Make a difference

Your gift to MD Anderson makes a difference in the lives of cancer patients by supporting innovative patient care, research, education and prevention programs. You can Donate Now or learn more at myGiving to MD Anderson.

© 2015 The University of Texas MD Anderson Cancer Center